相关实验视频
Updated: Jul 15, 2025

Chronic Salmonella Infection Induced Intestinal Fibrosis
Published on: September 22, 2019
在患有炎症性肠病的患者中,COVID-19疫苗接种后的疾病爆发
Yuichiro Yoshida1, Shin Fujioka2, Tomohiko Moriyama3
1Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Kyushu University, Japan.
对于患有炎性肠病 (IBD) 的患者来说,COVID-19疫苗接种通常是安全的. 接种疫苗后IBD的爆发很少见,尽管建议在接种疫苗后一周监测症状.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 疫苗学 疫苗学 疫苗学
背景情况:
- 炎症性肠病 (IBD) 包括性结肠炎 (UC) 和克罗恩病 (CD).
- 冠状病毒病2019 (COVID-19) 疫苗接种对IBD活动的影响尚未完全理解.
- 人们担心在接种COVID-19疫苗后可能出现IBD爆发.
研究的目的:
- 调查COVID-19疫苗接种后IBD爆发的发生率和特征.
- 评估IBD患者接种COVID-19疫苗的安全性.
主要方法:
- 从2021年10月到2022年2月,对411名IBD患者进行了回顾性研究.
- 对188名UC和119名CD患者的集中分析,这些患者在临床缓解期间接种了疫苗.
- 在接种疫苗后的30天内监测IBD病程.
主要成果:
- 观察到IBD爆发的发病率较低:UC患者中的4.3%,CD患者中的0.8%.
- 大多数爆发 (88.9%) 发生在接种疫苗后一周内.
- 两名患者需要住院治疗,一名CD患者需要手术.
结论:
- 由于爆发风险较低,建议IBD患者接种COVID-19疫苗.
- 临床医生应在接种疫苗后一周内对潜在的IBD爆发保持警,特别是在UC患者中.
更多相关视频
07:34Induction of Intestinal Inflammation by Adoptive Transfer of CBir1 TCR Transgenic CD4+ T Cells to Immunodeficient Mice
Published on: December 16, 2021
08:24Injections of Lipopolysaccharide into Mice to Mimic Entrance of Microbial-derived Products After Intestinal Barrier Breach
Published on: May 2, 2018
相关概念视频
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF